Processa Names Gujrathi Executive Chair, Adds Generian FcRn Program, Extends Runway to 2H 2029
PCSA sits 87% above its 52-week low of $1.041 on light trading volume (0.3× avg).
Summary
Processa appointed Vidya founder Sheila Gujrathi as Executive Chair, signed an option-based research collaboration with Generian for an oral FcRn program, and said its cash now lasts into the second half of 2029.
Key Events · Executive and Board Changes · PCSA
-
Gujrathi Named Executive Chair
Sheila Gujrathi, M.D., Vidya's founder and a board member since the June 2026 acquisition, became non-employee Executive Chair on October 28, 2026. Justin Yorke resigned as chair but remains a director.
-
Generian FcRn Collaboration Signed
Processa entered a research collaboration and exclusive option agreement with Generian Pharmaceuticals covering an oral macrocyclic peptide-based neonatal Fc receptor antagonist program for IgG-mediated autoimmune diseases.
-
Cash Runway Extended to 2H 2029
Management expects current cash resources, including the approximately $200 million private placement done alongside the Vidya acquisition, to fund operations into the second half of 2029.
-
CSU Phase 2 Design Set
The FDA cleared the IND for VT-7208 in chronic spontaneous urticaria; the planned trial is a 12-week, randomized, double-blind, placebo-controlled study of about 120 adults not controlled on H1 antihistamines.
Analysis · PCSA · Life Sciences
Fresh off the Vidya merger, Processa is installing new leadership and adding a second pipeline asset. Dr. Sheila Gujrathi, Vidya's founder, takes over as Executive Chair from Justin Yorke, who stays on the board — a signal the post-merger company will be run around the Vidya team and its BTK inhibitor VT-7208. The Generian deal adds an oral FcRn antagonist program on an option structure, so cash outlay is limited until the science matures. Most concretely, management now says the roughly $200 million raised alongside the Vidya acquisition funds operations into the second half of 2029, which removes near-term financing pressure. The FDA's clearance of the CSU IND was already reported today, so the new information here is governance, pipeline breadth and runway.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCSA was trading at $1.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $1.04 to $10.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.